Final trial results show promising long-term survival with lenvatinib plus pembrolizumab in advanced thymic tumors
Final results from the phase 2 PECATI clinical trial demonstrate encouraging long-term survival outcomes with the combination of lenvatinib and pembrolizumab in patients with previously treated advanced B3-thymoma and thymic carcinoma.
Recent trial findings suggest a promising combination of lenvatinib and pembrolizumab may offer long-term survival benefits for patients with advanced thymic tumors after initial platinum-based chemotherapy. The phase 2 PECATI trial, published in the Journal of Thoracic Oncology, detailed 40.2 months median overall survival and 22.1 months median progression-free survival, with 44.2% of the 43 participants experiencing grade 3 or higher adverse events.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
